Antiemetics

Chemotherapy-induced Nausea & Vomiting Drugs Market, 2024 - Focus on Serotonin & NK1 Receptor Antagonists and Other Therapies

Wednesday, August 12, 2020 - 5:30pm

DUBLIN, Aug. 12, 2020 /PRNewswire/ -- The "Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 12, 2020 /PRNewswire/ -- The "Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • The global chemotherapy-induced nausea and vomiting drugs market is poised to grow by $525 million during 2020-2024, progressing at a CAGR of 5% during the forecast period.
  • The study identifies the growing preference for chemotherapy drugs in developing countries as one of the prime reasons driving chemotherapy-induced nausea and vomiting drugs market growth during the next few years.
  • The chemotherapy-induced nausea and vomiting drugs market analysis includes therapy segment and geographic landscapes.

Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024: Anticipated to Grow by $525 Million - ResearchAndMarkets.com

Tuesday, August 11, 2020 - 4:20pm

The "Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • The global chemotherapy-induced nausea and vomiting drugs market is poised to grow by $525 million during 2020-2024, progressing at a CAGR of 5% during the forecast period.
  • The study identifies the growing preference for chemotherapy drugs in developing countries as one of the prime reasons driving chemotherapy-induced nausea and vomiting drugs market growth during the next few years.
  • The chemotherapy-induced nausea and vomiting drugs market analysis includes therapy segment and geographic landscapes.

Biotechnology Startup Cannformatics Expands Advisory Board with Nationally Recognized Experts in Clinical Medicine and Pediatric Neuropsychology

Tuesday, August 11, 2020 - 1:00pm

SAN FRANCISCO, Aug. 11, 2020 /PRNewswire-PRWeb/ --Cannformatics, an early stage biotech startup pioneering the use of metabolomics and AI to personalize medical cannabis treatments, today announced two new members to the company's advisory board.

Key Points: 
  • SAN FRANCISCO, Aug. 11, 2020 /PRNewswire-PRWeb/ --Cannformatics, an early stage biotech startup pioneering the use of metabolomics and AI to personalize medical cannabis treatments, today announced two new members to the company's advisory board.
  • The company welcomes nationally recognized board-certified emergency medicine physician Dr. Myiesha Taylor and University of California, San Francisco Assistant Professor Dr. Stephany Cox.
  • Taylor and Cox will provide scientific review and high-level advice to Cannformatics' management with regards to its upcoming autism pilot study as well as other R&D activities.
  • "Cannformatics is at the forefront of identifying cannabis-responsive biomarkers found in saliva and applying them to personalized medical cannabis recommendations.

Revivid USA Announces Launch of Two New CBD Gummy Products

Friday, August 7, 2020 - 4:00pm

EVERGREEN, Colo., Aug. 7, 2020 /PRNewswire-PRWeb/ -- Revivid USA , the leading Hemp brand of CBD oil, is pleased to announce the release of two new products.

Key Points: 
  • EVERGREEN, Colo., Aug. 7, 2020 /PRNewswire-PRWeb/ -- Revivid USA , the leading Hemp brand of CBD oil, is pleased to announce the release of two new products.
  • Revivid Whole Full-Spectrum CBD Gummies and Revivid Sport THC-Free CBD Gummies join the company's already established range of CBD Oil Tinctures, CBD Softgels, and CBD Topical creams.
  • Revivid Whole CBD Gummies (40ct) are full-spectrum, ensuring all of the plant's cannabinoids have been preserved in the final product.
  • The athlete-tailored Revivid Sport CBD Gummies (40ct) are THC-free and made from 99.9% pure CBD Isolate, which is tested at the company's Colorado base to ensure it does not contain other cannabinoids.

MediPharm Labs Announces Voting Results From the 2020 Annual and Special Meeting of Shareholders

Wednesday, August 5, 2020 - 10:00pm

Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.

Key Points: 
  • Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.
  • As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing commercialization of its Australian extraction facility.
  • CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
    This news release contains forward-looking information and forward-looking statements (collectively, forward-looking statements) within the meaning of the applicable Canadian securities legislation.
  • Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

University of Pittsburgh and Parallel, a Leading Cannabis Company, Join Forces in Pennsylvania Medical Marijuana Research Program

Wednesday, August 5, 2020 - 5:20pm

The University of Pittsburgh School of Medicine (Pitt) is one of eight Pennsylvania academic research universities approved to conduct clinical research in association with the commonwealth's medical marijuana program.

Key Points: 
  • The University of Pittsburgh School of Medicine (Pitt) is one of eight Pennsylvania academic research universities approved to conduct clinical research in association with the commonwealth's medical marijuana program.
  • "Pennsylvania's medical marijuana lawemphasizesthe need for rigorousresearch related to the use of medical cannabis," Shekhar continued.
  • "Parallel is pioneering the development of cannabis therapies through strategic partnerships with leading institutions such as the University of Pittsburgh.
  • Pitt will begin its medical marijuana research program with a clinical trial in patients who suffer from sickle cell disease (SCD).

N.M. Medical Cannabis Program Surpasses $92M for the First Six Months of 2020

Tuesday, August 4, 2020 - 6:56pm

The Lynn and Erin Compassionate Use Act mandates the NMDOH must ensure the uninterrupted availability of cannabis for a period of three months [90 days].

Key Points: 
  • The Lynn and Erin Compassionate Use Act mandates the NMDOH must ensure the uninterrupted availability of cannabis for a period of three months [90 days].
  • The level of available spending could ultimately impact the amount of medical cannabis purchased in the second half of 2020.
  • The New Mexico Medical Cannabis Program as compared to other states falls substantially behind in regard to patient-centric protections.
  • Ultra Health is New Mexicos #1 Cannabis Company and the largest vertically integrated medical cannabis provider in the United States.

Isiah Thomas Announces One World Pharma’s First THC Harvest

Monday, August 3, 2020 - 2:00pm

The harvest utilized a THC quota granted to One World Pharma by the Colombian government.

Key Points: 
  • The harvest utilized a THC quota granted to One World Pharma by the Colombian government.
  • OWP received its THC quota in December of 2019 and planted the psychoactive seeds in February of this year.
  • Most importantly, the successful completion of a full THC harvest allows the Company to now approach companies in legal countries which allow THC for medicinal use or pharmaceutical companies in need of THC ingredients for research and product development.
  • This first harvest is a milestone of significant importance for One World Pharma, stated Isiah Thomas, CEO, One World Pharma.

FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease

Saturday, August 1, 2020 - 2:06am

Epidiolex was previously approved for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS).

Key Points: 
  • Epidiolex was previously approved for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS).
  • This is the only FDA-approved drug that contains a purified drug substance derived from cannabis.
  • It is also the second FDA approval of a drug for the treatment of seizures associated with TSC.
  • It is THC (and not CBD) that is the primary psychoactive component of cannabis.

Redwood City’s First Licensed Cannabis Delivery Company Expands

Friday, July 31, 2020 - 2:00pm

Located at the heart of the San Francisco Peninsula, this location brings legal cannabis delivery to an underserviced area where surrounding cities have yet to adopt commercial cannabis activity.

Key Points: 
  • Located at the heart of the San Francisco Peninsula, this location brings legal cannabis delivery to an underserviced area where surrounding cities have yet to adopt commercial cannabis activity.
  • In addition to their Redwood City location, Juva Life has received state approval for cannabis delivery in Stockton, CA, and is locally approved for delivery and storefront retail in Hayward, CA.
  • John Hutar, President of the San Mateo County/Silicon Valley Convention and Visitors Bureau, noted, Juva Delivery was the first cannabis company to join the Convention and Visitors Bureau.
  • Juva Delivery (Redwood City) is a BCC-licensed delivery service: C9-0000289-LIC.